Larimar Therapeutics (LRMR) Debt to Equity (2016 - 2020)
Larimar Therapeutics (LRMR) has disclosed Debt to Equity for 6 consecutive years, with $5.36 as the latest value for Q3 2019.
- For the quarter ending Q3 2019, Debt to Equity rose 3206.8% year-over-year to $5.36, compared with a TTM value of $5.36 through Sep 2019, up 3206.8%, and an annual FY2018 reading of $5.21, up 1937.96% over the prior year.
- Debt to Equity was $5.36 for Q3 2019 at Larimar Therapeutics, down from $21.83 in the prior quarter.
- Across five years, Debt to Equity topped out at $21.83 in Q2 2019 and bottomed at $0.01 in Q3 2016.
- Average Debt to Equity over 5 years is $2.98, with a median of $0.16 recorded in 2018.
- The sharpest move saw Debt to Equity plummeted 65.48% in 2015, then surged 6037.58% in 2019.
- Year by year, Debt to Equity stood at $0.02 in 2015, then tumbled by 54.85% to $0.01 in 2016, then skyrocketed by 2673.76% to $0.26 in 2017, then skyrocketed by 1937.96% to $5.21 in 2018, then rose by 2.84% to $5.36 in 2019.
- Business Quant data shows Debt to Equity for LRMR at $5.36 in Q3 2019, $21.83 in Q2 2019, and $11.05 in Q1 2019.